Cytek Biosciences Inc reports results for the quarter ended in March - Earnings Summary

Cytek Biosciences

09/05/2023 23:06

* Cytek Biosciences Inc  CTKB.OQ  reported quarterly
breakeven
results​​ per share for the quarter ended in March. The mean
expectation of four analysts for the quarter was for earnings of
3 cents per share.
    * Revenue rose 5.8% to $37.09 million from a year ago;
analysts
expected $47.15 million. 
    * Cytek Biosciences Inc's reported EPS for the quarter was a
loss
of 5 cents​.
    * The mean earnings estimate of analysts had risen by
about 12.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Cytek Biosciences Inc shares had risen by 26.2% this
quarter and
gained 13.6% so far this year.
    * The company reported a quarterly loss of $6.81 million.
    * Wall Street's median 12-month price target for Cytek
Biosciences
Inc is $14.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
9 at 10:06 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      0.03           0.00           Missed
 Dec. 31 2022      0.05           0.06           Beat
 Sep. 30 2022      0.02           0.04           Beat
 Jun. 30 2022      0.02           0.03           Beat